登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial
ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由中国医学科学院肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06245824,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 8
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(8 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Pathologically documented breast cancer that:
入选标准第 3 条
is confirmed as HER2-positive Immunohistochemistry 3+(IHC3+) or in situ hybridization+(ISH+) in the pathological examination/rechecking of primary lesions or metastatic lesions performed by the Research site's Patholog Laboratory;
入选标准第 5 条
No prior chemotherapy or HER2-targeted therapy for advanced or metastatic breast cancer or only 1 previous line of endocrine therapy in the metastatic setting. Participants who have received chemotherapy or HER2-targeted therapy in the neo-adjuvant or adjuvant setting are eligible if > 6 months from treatment to metastatic diagnosis
入选标准第 7 条
Female participants must be 1 year post-menopausal, surgically sterile, or using one highly effective form of birth control (a highly effective method of contraception is defined as one that can achieve a failure rate of less than 1% per year when used consistently and correctly). Women of childbearing potential who are sexually active with a non-sterilised male partner must agree to use one highly effective method of birth control from the time of screening and must agree to continue using such precautions for 7 months after the last dose of study treatment (see Table 4 for complete list of highly effective birth control methods). Female patients must refrain from egg cell donation and breastfeeding while on study and for 7 months after the last dose of study treatments. Non sterilised male partners of a woman of childbearing potential must use a male condom plus spermicide (condom alone in countries where spermicides are not approved) throughout this period. Not engaging in heterosexual activity (sexual abstinence) for the duration of the study and drug washout period is an acceptable practice if this is the preferred usual lifestyle of the participant; however, periodic or occasional abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception.
入选标准第 23 条
Male participants who intend to be sexually active with a female partner of childbearing potential must be surgically sterile or using an acceptable method of contraception (see Table 4) from the time of screening throughout the total duration of the study and the drug washout period (4 months after the last dose of study treatment) to prevent pregnancy in a partner. Male participants must not donate or bank sperm during this same time period. Not engaging in heterosexual activity (sexual abstinence) for the duration of the study and drug washout period is an acceptable practice if this is the preferred usual lifestyle of the participant; however, periodic or occasional abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception.
入选标准第 24 条
Previous IP(pyrotinib or T-DXd)assignment in the present study, or prior treatment with any other HER2 TKI agent.
排除标准第 2 条
Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
入选标准第 11 条
Absolute neutrophils count (ANC) ≥1.5x109/L (band neutrophil and segmented neutrophil), platelets ≥100x109/L and Hb ≥90g/L [no blood transfusion or no erythropoietin (EPO) dependence within 7 days before enrollment].
入选标准第 16 条
Hepatic: total bilirubin ≤1× upper limit of normal (ULN) if no liver metastases or <2×ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastases at baseline; Alkaline phosphatase, alanine transaminase (ALT) and aspartate transaminase (AST) ≤1.5 ULN (or ≤5 ULN in case of known liver involvement); Serum albumin ≥ 2.5 g/dL.
入选标准第 17 条
Renal: Creatinine clearance (CCr) ≥30mL/min as determined by Cockcroft-Gault (using actual body weight);
入选标准第 18 条
International normalized ratio (INR) and prothrombin time (PT) ≤1.5 times ULN for patients not receiving therapeutic anticoagulation
入选标准第 19 条
Participants with a medical history of myocardial infarction (MI) within 6 months before first exposure to study intervention, symptomatic congestive heart failure (New York Heart Association Class II to IV), participants with troponin levels above ULN at screening (as defined by the manufacturer), and without any myocardial related symptoms, should have a cardiologic consultation before enrollment to rule out MI.
排除标准第 27 条
Having at least one measurable lesion according to RECIST 1.1.
入选标准第 12 条
History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 5 years before the first dose of study treatment and of low potential risk for recurrence. Exceptions include basal cell carcinoma of the skin and squamous cell carcinoma of the skin that has undergone potentially curative therapy, adequately resected non-melanoma skin cancer, curatively treated in situ disease, other solid tumours curatively treated.
排除标准第 8 条
Has active primary immunodeficiency, known HIV infection, or active hepatitis B or C infection, such as those with serological evidence of viral infection within 28 days of Day 1 of Cycle 1. Participants positive for hepatitis C virus (HCV)antibody are eligible only if polymerase chain reaction is negative for HCV RNA. Participants should be tested for HIV prior to enrolment if required by local regulations or Institutional Review Board/Ethics Committee. Subjects with past or resolved hepatitis B virus (HBV) infection are eligible only if they meet all of the following criteria:
排除标准第 20 条
antibody to hepatitis B core antigen (+) (IgG or total Ig), HBV DNA undetectable,
排除标准第 22 条
Absence of HCV co-infection or history of HCV co-infection.
排除标准第 24 条
Negative pregnancy test (urine or serum) for women of childbearing potential who are sexually active with a non-sterilised male partner.
入选标准第 22 条
Pregnant or breastfeeding female participants.
排除标准第 35 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06245824,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Provision of informed consent prior to any study specific procedures Aged at least 18 years. Pathologically documented breast cancer that: is advanced or metastatic; is confirmed as HER2-positive Immunohistochemistry 3+(IHC3+) or in situ hybridization+(ISH+) in the pathological examination/rechecking of primary lesions or metastatic lesions performed by the Research site's Patholog Laboratory; hormone receptor (HR)-positive or HR-negative disease No prior chemotherapy or HER2-targeted therapy for advanced or metastatic breast cancer or only 1 previous line of endocrine therapy in the metastatic setting. Participants who have received chemotherapy or HER2-targeted therapy in the neo-adjuvant or adjuvant setting are eligible if > 6 months from treatment to metastatic diagnosis Asymptomatic or treated brain metastases not needing urgent neurosurgical intervention or dehydration treatment and glucocorticoid treatment is allowed: Untreated brain metastases (BM) at contrast brain screening MRI/CT Previously local therapy treated stable or progressing brain metastases (BM). Eastern Cooperative Oncology Group (ECOG) performance status 0-1. Having at least one measurable lesion according to RECIST 1.1. left ventricular ejection fraction ≥ 50% within 28 days at screening. Life expectancy ≥ 12 weeks at screening. Adequate organ and bone marrow function within 28 days before randomization/enrolment as described below. Organ and bone marrow function criteria must also be met when laboratory tests are repeated within 3 days before Cycle 1 Day 1. Note: Transfusion (red blood cell or platelet) or Granulocyte Colony-Stimulating Factor administration is not allowed within 2 weeks prior to the day on which marrow function is assessed: Absolute neutrophils count (ANC) ≥1.5x109/L (band neutrophil and segmented neutrophil), platelets ≥100x109/L and Hb ≥90g/L [no blood transfusion or no erythropoietin (EPO) dependence within 7 days before enrollment]. Hepatic: total bilirubin ≤1× upper limit of normal (ULN) if no liver metastases or <2×ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastases at baseline; Alkaline phosphatase, alanine transaminase (ALT) and aspartate transaminase (AST) ≤1.5 ULN (or ≤5 ULN in case of known liver involvement); Serum albumin ≥ 2.5 g/dL. Renal: Creatinine clearance (CCr) ≥30mL/min as determined by Cockcroft-Gault (using actual body weight); International normalized ratio (INR) and prothrombin time (PT) ≤1.5 times ULN for patients not receiving therapeutic anticoagulation Has adequate treatment washout period before screen, defined as: Male and female. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Negative pregnancy test (urine or serum) for women of childbearing potential who are sexually active with a non-sterilised male partner. Female participants must be 1 year post-menopausal, surgically sterile, or using one highly effective form of birth control (a highly effective method of contraception is defined as one that can achieve a failure rate of less than 1% per year when used consistently and correctly). Women of childbearing potential who are sexually active with a non-sterilised male partner must agree to use one highly effective method of birth control from the time of screening and must agree to continue using such precautions for 7 months after the last dose of study treatment (see Table 4 for complete list of highly effective birth control methods). Female patients must refrain from egg cell donation and breastfeeding while on study and for 7 months after the last dose of study treatments. Non sterilised male partners of a woman of childbearing potential must use a male condom plus spermicide (condom alone in countries where spermicides are not approved) throughout this period. Not engaging in heterosexual activity (sexual abstinence) for the duration of the study and drug washout period is an acceptable practice if this is the preferred usual lifestyle of the participant; however, periodic or occasional abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. Male participants who intend to be sexually active with a female partner of childbearing potential must be surgically sterile or using an acceptable method of contraception (see Table 4) from the time of screening throughout the total duration of the study and the drug washout period (4 months after the last dose of study treatment) to prevent pregnancy in a partner. Male participants must not donate or bank sperm during this same time period. Not engaging in heterosexual activity (sexual abstinence) for the duration of the study and drug washout period is an acceptable practice if this is the preferred usual lifestyle of the participant; however, periodic or occasional abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception.排除标准:Exclusion Criteria:
Ineligible for any of the agents on the study. Participants with contraindications to pyrotinib per local prescribing information or to T-DXd per the T-DXd Investigator's Brochure cannot be enrolled to the study. Previous IP(pyrotinib or T-DXd)assignment in the present study, or prior treatment with any other HER2 TKI agent. Prior exposure to antibody drug conjugate that comprises of an exatecan derivative that is a topoisomerase I inhibitor. Any concurrent anticancer treatment. A 3-week washout period is required for female participants using hormone replacement therapy and for participants receiving endocrine therapy for HR positive tumours. Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study. Refractory nausea, vomiting and diarrhea, chronic gastrointestinal disease, or previous significant bowel resection. Has substance abuse or any other medical conditions such as clinically significant cardiac or psychological conditions, that may, in the opinion of the investigator, interfere with the subject's participation in the clinical study or evaluation of the clinical study results. History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 5 years before the first dose of study treatment and of low potential risk for recurrence. Exceptions include basal cell carcinoma of the skin and squamous cell carcinoma of the skin that has undergone potentially curative therapy, adequately resected non-melanoma skin cancer, curatively treated in situ disease, other solid tumours curatively treated. Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤1 or baseline. Note: Participants may be enrolled with chronic, stable Grade 2 toxicities (defined as no worsening to >Grade 2 for at least 3 months prior to first exposure to study intervention and managed with standard of care treatment) that the investigator deems related to previous anticancer therapy, including: Chemotherapy-induced neuropathy Fatigue Residual toxicities from prior immuno-oncology treatment: Grade 1 or Grade 2 endocrinopathies which may include: Hypothyroidism/hyperthyroidism Type 1 diabetes Hyperglycemia Adrenal insufficiency Adrenalitis Skin hypopigmentation (vitiligo) Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms. Participants with clinically inactive brain metastases may be included in the study. Participants with treated brain metastases that are no longer symptomatic and who require no treatment with corticosteroids or anticonvulsants may be included in the study if they have recovered from the acute toxic effect of radiotherapy. A minimum of 2 weeks must have elapsed between the end of whole brain radiotherapy or stereotactic radiotherapy and enrollment. Has active primary immunodeficiency, known HIV infection, or active hepatitis B or C infection, such as those with serological evidence of viral infection within 28 days of Day 1 of Cycle 1. Participants positive for hepatitis C virus (HCV)antibody are eligible only if polymerase chain reaction is negative for HCV RNA. Participants should be tested for HIV prior to enrolment if required by local regulations or Institutional Review Board/Ethics Committee. Subjects with past or resolved hepatitis B virus (HBV) infection are eligible only if they meet all of the following criteria: HBsAg(-) (for > 6 months off anti-viral treatment), antibody to hepatitis B core antigen (+) (IgG or total Ig), HBV DNA undetectable, Absence of cirrhosis or fibrosis on prior imaging or biopsy, Absence of HCV co-infection or history of HCV co-infection. Access to a local Hepatitis B expert during and after the study. Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals. Participants with a medical history of myocardial infarction (MI) within 6 months before first exposure to study intervention, symptomatic congestive heart failure (New York Heart Association Class II to IV), participants with troponin levels above ULN at screening (as defined by the manufacturer), and without any myocardial related symptoms, should have a cardiologic consultation before enrollment to rule out MI. History of (non-infectious) interstitial lung disease(ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. Lung criteria: Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (eg, pulmonary emboli within 3 months of study enrolment, severe asthma, severe chronic obstructive pulmonary disorder (COPD), restrictive lung disease, pleural effusion, post Corona Virus Disease 2019 pulmonary fibrosis, etc,). Any autoimmune, connective tissue or inflammatory disorders (eg, rheumatoid arthritis, Sjogren's, sarcoidosis, etc.) where there is documented, or a suspicion of pulmonary involvement at the time of screening. Full details of the disorder should be recorded in the electronic Case Report Form (eCRF) for participants who are included in the study. Prior pneumonectomy. Receipt of live, attenuated vaccine (mRNA and replication deficient adenoviral vaccines are not considered attenuated live vaccines) within 30 days prior to the first exposure to study intervention. Note: Participants, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of study intervention. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements. Pregnant or breastfeeding female participants.
引自 ClinicalTrials.gov, NCT06245824, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06245824,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。